Bio-Path Holdings (BPTH) 2.20 $BPTH
Bio-Path Holdings to Join Russell 3000(R) and Global Indexes
GlobeNewswire - Mon Jun 20, 3:01PM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the Company is set to join the broad-market Russell 3000Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 27.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016
GlobeNewswire - Mon Jun 06, 8:00AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and autoimmune drugs, today announced that data from the Phase I study of BP1001 (Liposomal Grb2 Antisense) as a treatment for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) and the safety segment of the Phase II combination therapy of BP1001 and low-dose cytarabine (LDAC) as a treatment for advanced AML were presented by Dr. Maro Ohanian, Assistant Professor at the University of Texas MD Anderson Cancer Center, during a poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in a poster titled, "Phase I Study of BP1001 (Liposomal Grb2 Antisense) in Patients with Hematologic Malignancies."
BPTH: 2.20 (+0.02)
Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster discussion presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 3-7, 2016 in Chicago, IL. Dr. Maro Ohanian, Assistant Professor at the University of Texas MD Anderson Cancer Center will present data from the Company's completed Phase I clinical trial and from the safety segment of the Phase II trial of BP1001 in combination with low-dose cytarabine (LDAC), including initial efficacy results. Notably, there were no dose-limiting toxicities observed in the safety segment and three of the six evaluable acute myeloid leukemia (AML) patients achieved complete remission, suggesting possible AML disease inhibition.
BPTH: 2.20 (+0.02)
Bio-Path reports 1Q loss
Automated Insights - Wed May 11, 6:39AM CDT
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.9 million in its first quarter.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2016 and also provided an update on recent corporate developments.
BPTH: 2.20 (+0.02)
Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:45AM CDT
With the Q1 cycle nearing its end, the earnings picture is becoming increasingly clear. While the going looked tough at the onset of the last month, that scenario has changed over the past few weeks.
CRME: 4.99 (-0.01), JNJ: 116.06 (-1.32), EARS: 3.82 (-0.18), GILD: 80.49 (-2.88), BITI: 25.80 (-0.71), BPTH: 2.20 (+0.02), AMGN: 146.75 (-5.52), ACRS: 18.00 (-0.21), ACOR: 25.34 (-0.97), NVS: 77.73 (-2.94)
Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
GlobeNewswire - Thu May 05, 7:01AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Ana Tari Ashizawa, Ph.D., Director of Research, will deliver an oral presentation titled, "Clinical Studies of BP1001, a drug candidate utilizing DNAbilize(TM) Antisense DNA Technology, in Hematologic Malignancies," at the 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference. Dr. Ashizawa's presentation will take place on Thursday, May 12th at 2pm Pacific Time at the Long Beach Convention and Entertainment Center in Long Beach, CA.
BPTH: 2.20 (+0.02)
Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016
GlobeNewswire - Wed May 04, 7:00AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 11, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center
BusinessWire - Wed Mar 23, 7:55AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"
, a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid drugs, today announced that it has entered a sponsored research agreement with The University of Texas Southwestern Medical Center (UT Southwestern) to evaluate Bio-Path's clinical pipeline for its efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. SLE is a chronic autoimmune disorder that presents an array of symptoms, including skin lesions, heart inflammation, joint pain, kidney failure and neuropsychiatric disorders. Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path's lead product candidate, which is currently in a Phase II study for blood cancers.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution
BusinessWire - Tue Mar 08, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path" , a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered a sponsored research agreement with The University of Texas MD Anderson Cancer Center ("MD Anderson" to evaluate Bio-Path's clinical pipeline for its ability to modulate pancreatic cancer. Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path's lead product candidate, which is currently in a Phase II study for blood cancers.
BPTH: 2.20 (+0.02)
Bio-Path Holdings to Present at the 28th Annual ROTH Conference
BusinessWire - Mon Mar 07, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path" , a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will deliver a company overview at the 28th Annual ROTH Conference in Dana Point, California on Monday, March 14 at 4:30 p.m. Pacific Time (1:30 p.m. Eastern Time).
BPTH: 2.20 (+0.02)
Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia
BusinessWire - Thu Mar 03, 7:55AM CST
--Company working to open a multi-site Phase II clinical trial to assess efficacy
BPTH: 2.20 (+0.02)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.46 (+0.02), AMBX: (), CLDX: 4.40 (-0.17), ARQL: 1.92 (unch), CTIC: 0.36 (-0.04), CTMX: 9.73 (+0.09), ABBV: 59.56 (-1.75), XLRN: 33.72 (-1.32), ADXS: 7.97 (-0.20), AMGN: 146.75 (-5.52), BIND: 0.40 (unch), BMY: 70.79 (-1.85), BPTH: 2.20 (+0.02), AZN: 27.89 (-1.40), AVEO: 0.94 (-0.04), CELGZ: 1.29 (-0.16)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.81 (-0.02), AMGN: 146.75 (-5.52), EPZM: 9.87 (-0.57), LLY: 74.22 (+0.28), ATRA: 21.26 (-0.80), GSK: 41.07 (-1.49), BMY: 70.79 (-1.85), ATNM: 1.73 (-0.02), CYCC: 5.18 (-0.09), BLCM: 12.44 (-0.55), BPTH: 2.20 (+0.02), CALA: 4.06 (-0.15), ABBV: 59.56 (-1.75), BXLT: 46.02 (-0.18), CBMG: 13.21 (-1.03)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 10.20 (-0.73), AMBX: (), CLBS: 0.52 (-0.01), CANF: 2.61 (-0.06), APTO: 2.34 (-0.10), AVXL: 4.51 (+0.24), BPTH: 2.20 (+0.02), AZN: 27.89 (-1.40), CYAD: 43.01 (-0.70)
Bio-Path Holdings to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Mon Feb 01, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path" , a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the 18th Annual BIO CEO & Investor Conference in New York City on Monday, February 8 at 5:00 p.m. Eastern Time.
BPTH: 2.20 (+0.02)
Follicular Lymphoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/38wlhh/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AbbVie Inc. - Affimed Therapeutics AG - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bio-Path Holdings, Inc. - Biocon Limited - Biogenomics Limited - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Curis, Inc. - Dynavax Technologies Corporation - (30 Others) Key Topics Covered: - Introduction - Follicular Lymphoma Overview - Therapeutics Development - Pipeline Products for Follicular Lymphoma - Overview - Pipeline Products for Follicular Lymphoma - Comparative Analysis - Follicular Lymphoma - Therapeutics under Development by Companies - Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes - Follicular Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Follicular Lymphoma - Products under Development by Companies - Follicular Lymphoma - Products under Investigation by Universities/Institutes - Follicular Lymphoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/38wlhh/follicular
DVAX: 13.95 (-1.06), CRIS: 1.58 (-0.08), BPTH: 2.20 (+0.02), ABBV: 59.56 (-1.75), CTIC: 0.36 (-0.04), BMY: 70.79 (-1.85), CBMG: 13.21 (-1.03), CHRS: 15.19 (-1.28), CELGZ: 1.29 (-0.16)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 146.75 (-5.52), ATRA: 21.26 (-0.80), STML: 6.87 (-0.23), SNTA: 0.31 (unch), ATNM: 1.73 (-0.02), SNDX: 10.85 (-0.67), BLCM: 12.44 (-0.55), BPTH: 2.20 (+0.02), TEVA: 50.02 (-1.35), AGIO: 45.33 (-3.17), XLRN: 33.72 (-1.32), ARRY: 3.47 (-0.11)
Bio-Path Holdings to Present at Biotech Showcase(TM) 2016
BusinessWire - Wed Jan 06, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path" , a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase(TM) 2016 in San Francisco on Wednesday, January 13, 2016 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time).
BPTH: 2.20 (+0.02)
Bio-Path Holdings to Join Russell 3000(R) and Global Indexes
GlobeNewswire - Mon Jun 20, 3:01PM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the Company is set to join the broad-market Russell 3000Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 27.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016
GlobeNewswire - Mon Jun 06, 8:00AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and autoimmune drugs, today announced that data from the Phase I study of BP1001 (Liposomal Grb2 Antisense) as a treatment for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) and the safety segment of the Phase II combination therapy of BP1001 and low-dose cytarabine (LDAC) as a treatment for advanced AML were presented by Dr. Maro Ohanian, Assistant Professor at the University of Texas MD Anderson Cancer Center, during a poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in a poster titled, "Phase I Study of BP1001 (Liposomal Grb2 Antisense) in Patients with Hematologic Malignancies."
BPTH: 2.20 (+0.02)
Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu May 19, 6:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster discussion presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 3-7, 2016 in Chicago, IL. Dr. Maro Ohanian, Assistant Professor at the University of Texas MD Anderson Cancer Center will present data from the Company's completed Phase I clinical trial and from the safety segment of the Phase II trial of BP1001 in combination with low-dose cytarabine (LDAC), including initial efficacy results. Notably, there were no dose-limiting toxicities observed in the safety segment and three of the six evaluable acute myeloid leukemia (AML) patients achieved complete remission, suggesting possible AML disease inhibition.
BPTH: 2.20 (+0.02)
Bio-Path reports 1Q loss
Automated Insights - Wed May 11, 6:39AM CDT
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.9 million in its first quarter.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2016 and also provided an update on recent corporate developments.
BPTH: 2.20 (+0.02)
Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:45AM CDT
With the Q1 cycle nearing its end, the earnings picture is becoming increasingly clear. While the going looked tough at the onset of the last month, that scenario has changed over the past few weeks.
CRME: 4.99 (-0.01), JNJ: 116.06 (-1.32), EARS: 3.82 (-0.18), GILD: 80.49 (-2.88), BITI: 25.80 (-0.71), BPTH: 2.20 (+0.02), AMGN: 146.75 (-5.52), ACRS: 18.00 (-0.21), ACOR: 25.34 (-0.97), NVS: 77.73 (-2.94)
Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
GlobeNewswire - Thu May 05, 7:01AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Ana Tari Ashizawa, Ph.D., Director of Research, will deliver an oral presentation titled, "Clinical Studies of BP1001, a drug candidate utilizing DNAbilize(TM) Antisense DNA Technology, in Hematologic Malignancies," at the 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference. Dr. Ashizawa's presentation will take place on Thursday, May 12th at 2pm Pacific Time at the Long Beach Convention and Entertainment Center in Long Beach, CA.
BPTH: 2.20 (+0.02)
Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016
GlobeNewswire - Wed May 04, 7:00AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 11, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.
BPTH: 2.20 (+0.02)
Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center
BusinessWire - Wed Mar 23, 7:55AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"
, a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid drugs, today announced that it has entered a sponsored research agreement with The University of Texas Southwestern Medical Center (UT Southwestern) to evaluate Bio-Path's clinical pipeline for its efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. SLE is a chronic autoimmune disorder that presents an array of symptoms, including skin lesions, heart inflammation, joint pain, kidney failure and neuropsychiatric disorders. Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path's lead product candidate, which is currently in a Phase II study for blood cancers. BPTH: 2.20 (+0.02)
Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution
BusinessWire - Tue Mar 08, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"
, a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered a sponsored research agreement with The University of Texas MD Anderson Cancer Center ("MD Anderson" to evaluate Bio-Path's clinical pipeline for its ability to modulate pancreatic cancer. Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path's lead product candidate, which is currently in a Phase II study for blood cancers. BPTH: 2.20 (+0.02)
Bio-Path Holdings to Present at the 28th Annual ROTH Conference
BusinessWire - Mon Mar 07, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"
, a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will deliver a company overview at the 28th Annual ROTH Conference in Dana Point, California on Monday, March 14 at 4:30 p.m. Pacific Time (1:30 p.m. Eastern Time). BPTH: 2.20 (+0.02)
Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia
BusinessWire - Thu Mar 03, 7:55AM CST
--Company working to open a multi-site Phase II clinical trial to assess efficacy
BPTH: 2.20 (+0.02)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.46 (+0.02), AMBX: (), CLDX: 4.40 (-0.17), ARQL: 1.92 (unch), CTIC: 0.36 (-0.04), CTMX: 9.73 (+0.09), ABBV: 59.56 (-1.75), XLRN: 33.72 (-1.32), ADXS: 7.97 (-0.20), AMGN: 146.75 (-5.52), BIND: 0.40 (unch), BMY: 70.79 (-1.85), BPTH: 2.20 (+0.02), AZN: 27.89 (-1.40), AVEO: 0.94 (-0.04), CELGZ: 1.29 (-0.16)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.81 (-0.02), AMGN: 146.75 (-5.52), EPZM: 9.87 (-0.57), LLY: 74.22 (+0.28), ATRA: 21.26 (-0.80), GSK: 41.07 (-1.49), BMY: 70.79 (-1.85), ATNM: 1.73 (-0.02), CYCC: 5.18 (-0.09), BLCM: 12.44 (-0.55), BPTH: 2.20 (+0.02), CALA: 4.06 (-0.15), ABBV: 59.56 (-1.75), BXLT: 46.02 (-0.18), CBMG: 13.21 (-1.03)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 10.20 (-0.73), AMBX: (), CLBS: 0.52 (-0.01), CANF: 2.61 (-0.06), APTO: 2.34 (-0.10), AVXL: 4.51 (+0.24), BPTH: 2.20 (+0.02), AZN: 27.89 (-1.40), CYAD: 43.01 (-0.70)
Bio-Path Holdings to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Mon Feb 01, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"
, a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the 18th Annual BIO CEO & Investor Conference in New York City on Monday, February 8 at 5:00 p.m. Eastern Time. BPTH: 2.20 (+0.02)
Follicular Lymphoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/38wlhh/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AbbVie Inc. - Affimed Therapeutics AG - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bio-Path Holdings, Inc. - Biocon Limited - Biogenomics Limited - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Curis, Inc. - Dynavax Technologies Corporation - (30 Others) Key Topics Covered: - Introduction - Follicular Lymphoma Overview - Therapeutics Development - Pipeline Products for Follicular Lymphoma - Overview - Pipeline Products for Follicular Lymphoma - Comparative Analysis - Follicular Lymphoma - Therapeutics under Development by Companies - Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes - Follicular Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Follicular Lymphoma - Products under Development by Companies - Follicular Lymphoma - Products under Investigation by Universities/Institutes - Follicular Lymphoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/38wlhh/follicular
DVAX: 13.95 (-1.06), CRIS: 1.58 (-0.08), BPTH: 2.20 (+0.02), ABBV: 59.56 (-1.75), CTIC: 0.36 (-0.04), BMY: 70.79 (-1.85), CBMG: 13.21 (-1.03), CHRS: 15.19 (-1.28), CELGZ: 1.29 (-0.16)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 146.75 (-5.52), ATRA: 21.26 (-0.80), STML: 6.87 (-0.23), SNTA: 0.31 (unch), ATNM: 1.73 (-0.02), SNDX: 10.85 (-0.67), BLCM: 12.44 (-0.55), BPTH: 2.20 (+0.02), TEVA: 50.02 (-1.35), AGIO: 45.33 (-3.17), XLRN: 33.72 (-1.32), ARRY: 3.47 (-0.11)
Bio-Path Holdings to Present at Biotech Showcase(TM) 2016
BusinessWire - Wed Jan 06, 7:55AM CST
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"
, a biotechnology company leveraging its proprietary DNAbilize(TM) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase(TM) 2016 in San Francisco on Wednesday, January 13, 2016 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time). BPTH: 2.20 (+0.02)
